Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Insights into clonal and CBC changes at disease evolution among ccus patients

Yazan Jabban, Rong He, Kurt Bessonen, Patricia Greipp, Dragan Jevremovic, David Viswanatha, James Foran, Talha Badar, Cecilia Arana Yi, Yael Kusne, Antoine Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, William Hogan, Abhishek Mangaonkar, Mithun Shah, Hassan Alkhateeb, Mrinal Patnaik, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 5621.

https://doi.org/10.1182/blood-2025-5621

Published: 2025

Journal Articles

Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML

Blood (2025) 146 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2025-7045

Published: 2025

Journal Articles

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

Blood (2025) 146 (Supplement 1): 5643.

https://doi.org/10.1182/blood-2025-5643

Published: 2025

Journal Articles

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Steven Tessier, Najla Al Ali, Michael Trinh, Andrew Brunner, Diletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza, David Sallman, Eric Padron, Zhuoer Xie, James Foran, Cecilia Arana Yi, Hassan Alkhateeb, Mithun Shah, Rami Komrokji, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 3864.

https://doi.org/10.1182/blood-2025-3864

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Blood (2025) 146 (Supplement 1): 766.

https://doi.org/10.1182/blood-2025-766

Published: 2025

Journal Articles

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Lindsay Rein, Nathan Boggs, Prithviraj Bose, Brian Modena, Vito Sabato, Karin Hartmann, Cem Akin, Tracy George, Cecilia Arana Yi, Hanneke Oude Elberink, Deepti Radia, Andreas Reiter, Miguel Piris-Villaespesa, Ingunn Dybedal, Jens Panse, Stephen Oh, Pankit Vachhani, Anthony Hunter, Mariana Castells, Cristina Bulai Livideanu, Paul van Daele, Arnold Kirshenbaum, Ivan Alvarez-Twose, Jennifer Vaughn, Minakshi Taparia, Sonia Cerquozzi, Andrzej Mital, Marek Hus, ALESSANDRA ROMANO, John Fahrenholz, Frederick Lansigan, Cristina Papayannidis, Helena Pomares, Michela Rondoni, Celalettin Ustun, Richard Herrscher, Michael Manning, Stéphane Barete, Mar Guilarte, Candido Rivera, Jonathan Bernstein, Peter Vadas, Chiara Elena, Derek McCulloch, Nina Orfali, Clodagh Keohane, Francesco Mannelli, Philippe Schafhausen, Amanda Pilla, Jenna Zhang, Lei Sun, Nisha Shah, Hina Jolin, Rachael Easton, Jessica Sachs, Frank Siebenhaar, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 80.

https://doi.org/10.1182/blood-2025-80

Published: 2025

Journal Articles

MAPS-R: International consensus classification-guided revision of the mayo alliance prognostic system for systemic mastocytosis

Ayalew Tefferi, Fnu Aperna, Mahesh Kumar, Maymona Abdelmagid, Joseph Butterfield, Thanai Pongdee, Cecilia Arana Yi, Daniel Arber, Attilio Orazi, Dong Chen, Kaaren Reichard, Naseema Gangat, Animesh Pardanani

Blood (2025) 146 (Supplement 1): 2017.

https://doi.org/10.1182/blood-2025-2017

Published: 2025

Journal Articles

Systemic mastocytosis with associated lymphoid neoplasms (SM-ALN): A distinct subset with indolent clinical course and favorable outcomes

Angel Luis OROSCO TTAMINA, Javier Munoz, Katalin Kelemen, Jeanne Palmer, Aref Al-Kali, Candido Rivera, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi, Cecilia Arana Yi

Blood (2025) 146 (Supplement 1): 7315.

https://doi.org/10.1182/blood-2025-7315

Published: 2025

Journal Articles

Clinical outcomes in adult AML with KMT2A rearrangements: A comparative analysis with R/R KMT2Ar and NPM1-mutated AML from the Mayo Clinic

Mahmood Aldapt, Kin Fentie, Joseph Parker, Hemant Murthy, James Foran, Naseema Gangat, Mohamed Kharfan-Dabaja, Jennifer Jiang, Yao-Shan Fan, Aref Al-Kali, Antoine Saliba, Cecilia Arana Yi, Nathan Punwani, Lisa Sproat, Mark Litzow, Mrinal Patnaik, Talha Badar

Blood (2025) 146 (Supplement 1): 7030.

https://doi.org/10.1182/blood-2025-7030

Published: 2025

Journal Articles

Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study

Blood (2025) 146 (Supplement 1): 7370.

https://doi.org/10.1182/blood-2025-7370

Published: 2025

Journal Articles

Predictors of symptom improvement in myeloproliferative neoplasms: A real-world retrospective cohort study

Muhammad Ali Khan, Muhammad Uzair Sarfraz, Muhammad Hussnain Sadiq, Fouad Nahhat, Japneet Kaur Oberoi, John Camoriano, Cecilia Arana Yi, Jennifer Andres, Joshua Blocher, Heidi Kosiorek, Irbaz Riaz, Jeanne Palmer

Blood (2025) 146 (Supplement 1): 3823.

https://doi.org/10.1182/blood-2025-3823

Published: 2025

Journal Articles

Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis

Blood (2025) 146 (Supplement 1): 3798.

https://doi.org/10.1182/blood-2025-3798

Published: 2025

Journal Articles

Post-FDA approval experience with momelotinib in JAK inhibitor-naïve myelofibrosis: Focus on anemia response and treatment-emergent nephropathy and peripheral neuropathy

Ayalew Tefferi, Maymona Abdelmagid, Jeanne Palmer, Aref Al-Kali, Cecilia Arana Yi, Aasiya Matin, Hassan Alkhateeb, Talha Badar, Yassin Bashir, Kaaren Reichard, Rong He, Animesh Pardanani, Naseema Gangat

Blood (2025) 146 (Supplement 1): 3791.

https://doi.org/10.1182/blood-2025-3791

Published: 2025

Journal Articles

CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients

Blood (2025) 146 (Supplement 1): 1602.

https://doi.org/10.1182/blood-2025-1602

Published: 2025

Journal Articles

The synonymous IDH1 p.Gly105Gly (rs11554137) variant associates with AML post-transplant relapse via aberrant signal transduction pathways

Blood (2025) 146 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2025-1699

Published: 2025

Journal Articles

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study

Tariq Kewan, Oudai Alkabbani, Rong He, Dragan Jevremovic, Patricia Greipp, Antoine Saliba, Aasiya Matin, Mehrdad Hefazi Torghabeh, Abhishek Mangaonkar, Naseema Gangat, William Hogan, Mrinal Patnaik, Hassan Alkhateeb, Cecilia Arana Yi, James Foran, Mark Litzow, Mithun Shah, Kebede Begna, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 996.

https://doi.org/10.1182/blood-2025-996

Published: 2025

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 12353–12354.

https://doi.org/10.1182/blood-2022-155561

Published: 2022

Journal Articles

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood (2022) 140 (Supplement 1): 2887–2890.

https://doi.org/10.1182/blood-2022-162367

Published: 2022

Journal Articles

Therapeutic Plasma Exchange for Apixaban Removal in the Setting of Delayed Clearance and Life-Threatening Bleeding

Michael T. Francisco, Cecilia Arana Yi, Leslie Padrnos, Shienna Braga, Jill Adamski

Blood (2021) 138 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2021-151835

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Insights into clonal and CBC changes at disease evolution among ccus patients

Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

MAPS-R: International consensus classification-guided revision of the mayo alliance prognostic system for systemic mastocytosis

Systemic mastocytosis with associated lymphoid neoplasms (SM-ALN): A distinct subset with indolent clinical course and favorable outcomes

Clinical outcomes in adult AML with KMT2A rearrangements: A comparative analysis with R/R KMT2Ar and NPM1-mutated AML from the Mayo Clinic

Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study

Predictors of symptom improvement in myeloproliferative neoplasms: A real-world retrospective cohort study

Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis

Post-FDA approval experience with momelotinib in JAK inhibitor-naïve myelofibrosis: Focus on anemia response and treatment-emergent nephropathy and peripheral neuropathy

CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients

The synonymous IDH1 p.Gly105Gly (rs11554137) variant associates with AML post-transplant relapse via aberrant signal transduction pathways

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study

Risk prediction for clonal cytopenia: multicenter real-world evidence

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Therapeutic Plasma Exchange for Apixaban Removal in the Setting of Delayed Clearance and Life-Threatening Bleeding

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only